Beam Therapeutics (BEAM) Q4 2025 earnings summary

Executive summary

• Announced expansion of the liver-targeted portfolio with BEAM-304, a new base editing program for PKU, targeting the two most common mutations and aiming to address a majority of PKU patients over time, with IND filing anticipated in 2026.

• Provided updates on the anticipated commercialization of risto-cel for sickle cell disease, supported by a new $500M strategic financing agreement with Sixth Street.

• Highlighted the modular, scalable nature of the base editing platform, enabling efficient development of therapies for multiple genetic diseases.

• Emphasized strong financial position with $1.25B in cash and marketable securities at year-end 2025 and a projected runway into mid-2029.

• Updated Phase 1/2 data and pivotal development for BEAM-302 in alpha-1 antitrypsin deficiency expected in Q1 2026.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1.25B as of December 31, 2025, up from $850.7M at year-end 2024.

• Secured up to $500M in long-term, non-dilutive capital from Sixth Street, with $100M funded at close and additional tranches tied to risto-cel milestones.

• R&D expenses were $99.3M for Q4 2025 and $409.6M for the full year, compared to $101.4M and $367.6M in 2024.

• G&A expenses were $32.3M for Q4 2025 and $113.8M for the year, up from $28.7M and $111.5M in 2024.

• Net income for Q4 2025 was $244.3M ($2.37 per basic share), while the full year saw a net loss of $80.0M ($0.81 per share).

Outlook and guidance

• IND filing for BEAM-304 in PKU expected in 2026, with initial focus on R408W mutation and plans to expand to additional mutations.

• BEAM-302 pivotal development update and risto-cel BLA submission anticipated by year-end 2026.

• Continued advancement of pipeline, including BEAM-301 data in GSD Ia and BEAM-103 healthy volunteer study.

• Cash runway expected to fund operations into mid-2029, covering major clinical and commercial milestones.